Day: January 5, 2023

Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2024 WARMINSTER, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced its 2023 corporate objectives and provided a financial update. William Collier, President and CEO of Arbutus Biopharma, stated, “Building upon our accomplishments in 2022, we are poised in this coming year to expand our clinical footprint in HBV with the initiation of clinical trials for two...

Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platform Submit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023 Submit IND application for NTLA-2002 for the treatment of hereditary angioedema (HAE) and initiate global Phase 2 study in 1H 2023 Present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies Progress first CRISPR-based gene insertion investigational therapy in humans; submit IND or equivalent filing for NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD) in 2H 2023 Ended 2022 in a strong financial position with...

CENTREVILLE, Va., Jan. 05, 2023 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company’s BlackHorse Solutions subsidiary won a $12 million contract from the Defense Advanced Research Projects Agency (DARPA) for a research project under the Signature Management using Operational Knowledge and Environments (SMOKE) program. The cost-plus-fixed-fee contract represents new work for the company and was secured through a competitive acquisition process. As cyber networks are under persistent threat from malicious cyber actors, Parsons will develop data-driven tools to automate the planning and execution of threat-emulated cyber infrastructure needed for network security assessments under the SMOKE program. “Our offensive and defensive cyberspace operations combine leading edge technical innovations, mission...

Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Significant Optionality for Omilancor, LABP-104 and Four Promising Pre-Clinical Programs Secures Additional $16.7 Million Investment Disciplined Financial Approach Expected to Maintain Cash Runway into First Half of 2025 Company to Host Investor Call at 8:00 AM ET NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a comprehensive update on...

Myriad Genetics continues to advance non-invasive prenatal screening with Prequel®and the forthcoming FirstGene™ test using AMPLIFY™ technologySALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a recent guideline update by the American College of Medical Genetics and Genomics (ACMG), reaffirming the clinical value of non-invasive prenatal screening (NIPS) for a range of chromosomal abnormalities. Myriad is dedicated to advancing NIPS with best-in-class technology and important product launches. ACMG continues to recommend offering screening for common trisomies (on chromosomes 13, 18, and 21) in all pregnancies, and newly updated guidance now provides a strong recommendation for offering screening...

HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT, Fr8Tech), a technology company developing solutions to optimize and automate the supply chain process and providing its Fr8App platform for B2B cross-border shipping in the USMCA region, announces guidance for revenue for 2023. The company projects 2023 revenue to be between $36 to $42 million, compared to preliminary 2022 revenue of approximately $26 to $27 million. Javier Selgas, CEO of Fr8Tech, said, “We look forward to continued growth in our cross-border and domestic FTL offerings over the course of the next 12 to 24 months and come into 2023 with a strong pipeline of existing customers and new prospects and growing lines of business. We are revising our guidance for 2023 revenues to be in the $36 to $42 million range as we continue to invest...

KRAKOW, Poland, Jan. 05, 2023 (GLOBE NEWSWIRE) — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced that Pawel Przewiezlikowski, Chief Executive Officer of Ryvu Therapeutics, will participate in the Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel Discussion entitled “European Partners Dream Big, Make Bold Progress” on Wednesday, January 18, 2023, at 12:00 p.m. Eastern Time. Vatnak Vat-Ho, Chief Business Officer of Ryvu, will also participate in the 12th Annual LifeSci Partners Corporate Access Event, taking place January 9-11, 2023, in San Francisco, California. Details on the upcoming events are as follows:The Leukemia & Lymphoma Society Therapy Acceleration Program®...

NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company. Dr. T.Z. (Ted) Chaung, a seasoned independent healthcare consultant with broad experience in healthcare industry startups, new drug development, venture capital, and business development, in both the Taiwan and U.S. healthcare sectors, has joined the Company’s advisory board. “We are excited to welcome the addition of Dr. Ted Chaung to our Advisory Board,”  stated Hestia...

ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) —  Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that its end-of-Phase 2 meeting request with the U.S. Food and Drug Administration (“FDA”) to discuss advancing IMC-1 into Phase 3 development as a treatment for FM has been scheduled for mid-March 2023. At this meeting, the Company will discuss with the FDA plans for a Phase 3 program that would support submission of a new drug application for IMC-1 for the treatment of FM. The Company plans to provide a program update by the end of April following the receipt of formal written feedback from the FDA. The Company believes the safety and efficacy results from its...

Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 Advancing solid tumor program with development of several TCRs for multiple HLAs across multiple targets; INDs filed for two MAGE-A1 TCRs (TSC-204-A0201 and TSC-204-C0702) as well as IND for multiplexing TCRs Cash runway funds operations into 2Q 2024 WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2023 clinical pipeline plans and highlighted recent corporate achievements. “We made significant progress and growth in 2022, positioning both our solid tumor...